RxDoctor Payments Data

Jason Berlin, PA

Physician Assistant · Halifax, PANPI 1841929247

Payments from drug & device makers

$8,988in general payments, 2019–2025

Across 439 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Lilly USA, LLC$886
  • Novo Nordisk$776
  • Boehringer Ingelheim$641
  • Pfizer$636
  • plus $3K from 30 others

What the payments were for

  • Food & beverage$8,976100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,988 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$10,592
Medicare patients
43
Services billed
187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin40$53,444
OzempicSemaglutide23$43,634
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$23,450
FarxigaDapagliflozin Propanediol15$17,496
EliquisApixaban26$17,116
TradjentaLinagliptin12$13,061
Atorvastatin Calcium141$2,099
Rosuvastatin Calcium28$2,019
Albuterol Sulfate HfaAlbuterol Sulfate48$1,522
ClopidogrelClopidogrel Bisulfate13$1,408
Losartan Potassium42$976
Levothyroxine Sodium56$830
Omeprazole60$742
Tamsulosin Hcl41$734
Pantoprazole Sodium30$542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$641$66,50652 claims
Novo NordiskOzempic$776$43,63423 claims
GSKTrelegy Ellipta$122$23,45027 claims
AstraZenecaFarxiga$1,730$17,49615 claims
PfizerEliquis$636$17,11626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Halifax

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →